pills.jpg

 

Clinical Development Programs

 

 

Breast Cancer

 

Our flagship program is developing GLG-302 (an NCE) and GLG-801 (a repurposed compound) in Triple Negative Breast Cancer (TNBC). Both have shown excellent preclinical activity as solitary or combinatorial agents against several breast cell lines and have demonstrated exciting tumor mass reductions in-vivo.  Non-GLP toxicology has been completed in dogs and rats with excellent tolerability and we are in the process of initiating a TNBC Phase I/II clinical trial with GLG-801. 

picture20.jpg

Chronic Lymphocytic Leukemia

 

Other programs include an ongoing Phase I/II trial of GLG-801 in Chronic Lymphocytic Leukemia (CLL) that has shown a favorable response profile and therapeutic index.

 

Ovarian Cancer

 

In Q42017 we initiated a preclinical program to apply our Gx-C3 platform for precision, patient-centric treatment of ovarian cancer.

 

Diffuse Intrinsic Pontine Glioma

 

We have initiated a Phase I/II study of GLG-801 for childhood Diffuse Intrinsic Pontine Glioma (DIPG) and other pediatric brain tumors, and in 3Q2018 we embarked on a grant funded mission to apply our Gx-C3 platform to DIPG in order to elevate the standard of care for this indication.

 HOME

medic_01.jpg